Orum Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Orum Therapeutics, Inc. - overview
Established
2016
Location
Daejeon, -, South Korea
Primary Industry
Biotechnology
About
Founded in 2016 and based in Daejeon, South Korea, Orum Therapeutics, Inc. develops a cell-penetrating antibody platform targeting specific cell types for treating genetic diseases and cancers. In February 2025, Orum Therapeutics, Inc. raised KRW 50 billion in an IPO, selling 2.
5 million shares at KRW 20,000 apiece, below the expected price range of KRW 24,000 and KRW 30,000 on the KOSDAQ. Orum Therapeutics, Inc. intends to utilize the capital raised in its February 2025 IPO to cover future research and development costs and general operating expenses starting in 2025, supplementing these needs with existing cash and expected revenue from technology‑licensing.
Current Investors
LB Investment, KB Investment, InterVest
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Epidemiology, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.orumrx.com/
Company Stage
Mature
Total Amount Raised
Subscriber access only
Orum Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.